Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous bone marrow-derived mononuclear cells (BM-MNCs) are an investigational cell therapy developed by the Tehran University of Medical Sciences for the treatment of ocular lesions in Behcet's Disease. The therapy involves the extraction of bone marrow from the patient's iliac crest, followed by the isolation and expansion of mononuclear cells, including mesenchymal stem cells. These cells are characterized by the expression of markers such as CD90, CD44, CD105, and CD166. The cells are administered via intravitreal injection, where they are hypothesized to exert immunomodulatory and regenerative effects to halt or reverse the progression of intractable inflammatory eye lesions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous bone marrow-derived mononuclear cells (Tehran University of Medical Sciences).